MGMijal Gutreiman

Mijal Gutreiman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mijal Gutreiman has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Iris Lavon

    Leslie and Michael Gaffin Center for Neuro-Oncology, Departments of Neurology and Oncology, Hadassah Hebrew University Medical Center , Jerusalem (I.L., A.L.); , Miami (N.S.); , Miami (N.S.); , Cleveland (J.D.L.); , Cleveland (J.D.L.); , Cleveland (J.D.L.); , Cleveland (J.D.L.); , Copenhagen (J.D.L.)

    1 shared publication
  • Michael Weller

    Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

    1 shared publication
  • Nomi Zalcman

    Molecular Neuro-Oncology Laboratory, Leslie and Michael Gaffin Center for Neuro-Oncology, Agnes Ginges Center for Human Neurogenetics, Neurology Department, Hadassah Hebrew University Medical Center, P.O. Box 12000, Jerusalem 91120, Israel

    1 shared publication
  • Tal Shahar

    Laboratory of Molecular Neuro Oncology, Neurosurgery Department Shaare Zedek Medical Center Jerusalem Israel

    1 shared publication

Latest Publications

  • Open Access

    Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target

    by Nomi Zalcman, Mijal Gutreiman, Tal Shahar, Michael Weller, Iris Lavon

    Androgen receptor (AR) is a ligand-mediated transcription factor that belongs to the superfamily of steroid receptors. AR is overexpressed in most glioblastomas and is a potential therapeutic target. In prostate and breast cancers, AR activation can be achieved also by a ligand-independent signaling through receptor tyrosine kinases such as epidermal growth factor receptor (EGFR). Considering its major role in glioblastoma, we explored whether EGFR is involved in AR signaling in this tumor. Analysis of mRNA expression in 28 glioblastoma samples with quantitative real-time reverse-transcription polymerase chain reaction revealed a positive and significant correlation between AR and EGFR mRNA expression levels (R = 0.47, p = 0.0092), which was validated by The Cancer Genome Atlas dataset (n = 671) analysis (R = 0.3, p = 0.00006). Using Western blotting and immunofluorescence staining, we showed that the transduced overexpression of EGFR or its variant EGFRvIII in the U87MG cells induced AR protein overexpression and nuclear translocation and Protein kinase B (AKT) S473 and AR S210/213 phosphorylation. The EGFR kinase inhibitor afatinib and the AKT inhibitor MK2206 reduced AR nuclear translocation. Afatinib diminished AKT phosphorylation at 30 min and 6 h in the EGFR- and EGFRvIII-overexpressing cells, respectively, and decreased AR phosphorylation in EGFR-overexpressing cells at 4 h. Afatinib or MK2206 combination therapy with the AR antagonist enzalutamide in the EGFR and EGFRvIII-overexpressing cells had synergistic efficacy. Our findings suggest that EGFR signaling is involved in AR activation in glioblastoma and buttresses the concept of combining an EGFR signaling inhibitor with AR antagonists as a potential glioblastoma treatment.